PointState Capital’s Cellectis CLLS Stock Holding History

PointState Capital’s Portfolio CLLS Stock Details CLLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-145,300	Closed	-$4.24M	–	161
2017 Q4	$4.24M	Buy	+145,300	New	+$3.96M	0.04%	118

Other funds holding CLLS

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Credit Suisse Zurich, Switzerland $104B AUM 34.76% 1-Year Est. Return

SFM

Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return

TCM

Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Lazard Asset Management New York $66.1B AUM 33.53% 1-Year Est. Return

Ascend Capital Orinda, California $1.99B AUM 10.37% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

PointState Capital's CLLS Position: Q1 2018 in Review

PointState Capital sold out of Cellectis (CLLS) in Q1 2018, closing a stake of 145,300 shares — an estimated $4.24M sold.

PointState Capital first reported a position in CLLS in Q4 2017 and held it in 1 quarter. The position peaked at $4.24M in Q4 2017. 69 funds tracked by Wall St. Rank hold CLLS as of Q1 2018.

PointState Capital reported no remaining Cellectis position as of Q1 2018 after selling out during the quarter.
PointState Capital sold 145,300 Cellectis shares in Q1 2018, an estimated $4.24M.
PointState Capital first reported a position in Cellectis in Q4 2017 and held it in 1 quarter.
PointState Capital's Cellectis position peaked at $4.24M in Q4 2017.
69 funds tracked by Wall St. Rank held Cellectis as of Q1 2018.

Based on PointState Capital's 13F filing for Q1 2018, filed 15 May 2018.